National Cancer Institute to Grant Exclusive Patent License to NE1 Inc for Cancer Immunotherapy

Summary

The National Cancer Institute is considering granting an exclusive patent license to NE1 Inc to use a personalized tumor vaccine for cancer immunotherapy, based on U.S. patents and patent applications.